IL280990A - Use of alpha-2 adrenergic receptor agonists to improve vision - Google Patents
Use of alpha-2 adrenergic receptor agonists to improve visionInfo
- Publication number
- IL280990A IL280990A IL280990A IL28099021A IL280990A IL 280990 A IL280990 A IL 280990A IL 280990 A IL280990 A IL 280990A IL 28099021 A IL28099021 A IL 28099021A IL 280990 A IL280990 A IL 280990A
- Authority
- IL
- Israel
- Prior art keywords
- alpha
- receptor agonists
- adrenergic receptor
- improving vision
- vision
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280990A true IL280990A (en) | 2021-04-29 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280990A IL280990A (en) | 2018-08-21 | 2021-02-21 | Use of alpha-2 adrenergic receptor agonists to improve vision |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20210205273A1 (enExample) |
| EP (1) | EP3840750A1 (enExample) |
| JP (1) | JP2021534217A (enExample) |
| KR (1) | KR20210047323A (enExample) |
| CN (1) | CN112823003A (enExample) |
| AR (1) | AR115991A1 (enExample) |
| AU (1) | AU2019325486A1 (enExample) |
| BR (1) | BR112021003295A2 (enExample) |
| CA (1) | CA3110318A1 (enExample) |
| CL (1) | CL2021000440A1 (enExample) |
| CO (1) | CO2021003460A2 (enExample) |
| IL (1) | IL280990A (enExample) |
| MX (1) | MX2021002112A (enExample) |
| PH (1) | PH12021550372A1 (enExample) |
| SG (1) | SG11202101730SA (enExample) |
| TW (1) | TW202021584A (enExample) |
| WO (1) | WO2020041340A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023514732A (ja) * | 2020-02-20 | 2023-04-07 | アラーガン、インコーポレイテッド | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| WO2012149381A1 (en) * | 2011-04-28 | 2012-11-01 | Alpha Synergy Development, Inc. | Compositions and methods for improving night vision |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| ES2751681T3 (es) | 2013-03-15 | 2020-04-01 | Allergan Inc | Implante intraocular que contiene prostamida |
| EP2978406A1 (en) | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| CN103338483B (zh) * | 2013-07-24 | 2016-08-10 | 成都西加云杉科技有限公司 | 数据分流方法、数据分流设备及异构网络 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en not_active Withdrawn
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt not_active IP Right Cessation
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en not_active Abandoned
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en not_active Ceased
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko not_active Withdrawn
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es not_active Application Discontinuation
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
-
2024
- 2024-03-08 US US18/599,800 patent/US20240358682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3110318A1 (en) | 2020-02-27 |
| WO2020041340A1 (en) | 2020-02-27 |
| CL2021000440A1 (es) | 2021-09-20 |
| EP3840750A1 (en) | 2021-06-30 |
| KR20210047323A (ko) | 2021-04-29 |
| BR112021003295A2 (pt) | 2021-05-18 |
| US20220288031A1 (en) | 2022-09-15 |
| AR115991A1 (es) | 2021-03-17 |
| SG11202101730SA (en) | 2021-03-30 |
| US20240358682A1 (en) | 2024-10-31 |
| AU2019325486A1 (en) | 2021-03-25 |
| US20210205273A1 (en) | 2021-07-08 |
| JP2021534217A (ja) | 2021-12-09 |
| PH12021550372A1 (en) | 2021-11-29 |
| TW202021584A (zh) | 2020-06-16 |
| CO2021003460A2 (es) | 2021-04-08 |
| MX2021002112A (es) | 2021-07-16 |
| CN112823003A (zh) | 2021-05-18 |
| US20220160623A1 (en) | 2022-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4069686C0 (en) | GLP-1 RECEPTOR AGONIST | |
| IL279300A (en) | 1-GLP agonist receptors and their use | |
| IL279224B1 (en) | 1-glp agonist receptors and their use | |
| SG11202013044PA (en) | Il2 agonists | |
| IL276918A (en) | Ophthalmic formulation | |
| DK3762380T3 (da) | Phenylpyrrolidinon-formylpeptid-2-receptoragonister | |
| IL292601A (en) | npy2 receptor agonists | |
| SG11202101730SA (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| PL3804653T3 (pl) | Goniometr oczny | |
| IL277243A (en) | Inverted pyrazoles are FFA4/GPR120 receptor agonists | |
| IL268008A (en) | Ppargamma agonist for the treatment of huntington's disease | |
| GB201820021D0 (en) | Ocular hydrogel compositions | |
| GB201805675D0 (en) | Compounds For Use As Apelin Receptor Antagonists | |
| ZAA201801093S (en) | Monitor console | |
| IL290024A (en) | Bicyclic cx3cr1 receptor agonists | |
| HK40056372A (en) | The use of alpha-2-adrenergic receptor agonists for improving vision | |
| IT201700006360A1 (it) | Composizione per uso oftalmico | |
| GB201903900D0 (en) | Adenosine receptor agonists | |
| PL3508211T3 (pl) | Kompozycja dla zdrowia oczu | |
| SMT202400035T1 (it) | Formulazione intravaginale | |
| GB201915837D0 (en) | Probe | |
| GB201817943D0 (en) | Galanin-2 receptor agonists | |
| HK40048019A (en) | Farnesoid x receptor agonists for the treatment of disease | |
| HK40039646A (en) | Synthetic rig-i-like receptor agonists | |
| HK40078505A (zh) | 合成rig-i样受体激动剂 |